CN1319574C - 一种治疗便秘的药物 - Google Patents
一种治疗便秘的药物 Download PDFInfo
- Publication number
- CN1319574C CN1319574C CNB2005100123568A CN200510012356A CN1319574C CN 1319574 C CN1319574 C CN 1319574C CN B2005100123568 A CNB2005100123568 A CN B2005100123568A CN 200510012356 A CN200510012356 A CN 200510012356A CN 1319574 C CN1319574 C CN 1319574C
- Authority
- CN
- China
- Prior art keywords
- constipation
- medicine
- medicament
- present
- aloe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 229940079593 drug Drugs 0.000 title description 9
- 241001116389 Aloe Species 0.000 claims abstract description 20
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 20
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 12
- 244000293323 Cosmos caudatus Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 19
- 210000003608 fece Anatomy 0.000 abstract description 4
- 231100000572 poisoning Toxicity 0.000 abstract description 4
- 230000000607 poisoning effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 229910052785 arsenic Inorganic materials 0.000 abstract 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 1
- 230000001186 cumulative effect Effects 0.000 abstract 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract 1
- 229910052753 mercury Inorganic materials 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 230000013872 defecation Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 208000019790 abdominal distention Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 210000002105 tongue Anatomy 0.000 description 9
- 206010000087 Abdominal pain upper Diseases 0.000 description 8
- 206010030302 Oliguria Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010002153 Anal fissure Diseases 0.000 description 5
- 208000016583 Anus disease Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000009531 Fissure in Ano Diseases 0.000 description 5
- 208000005946 Xerostomia Diseases 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 206010013781 dry mouth Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000009705 sanhuang Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020100 Hip fracture Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- POMKXWCJRHNLRP-DQMLXFRHSA-N Rheochrysin Chemical compound C=12C(=O)C3=C(O)C=C(C)C=C3C(=O)C2=CC(OC)=CC=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O POMKXWCJRHNLRP-DQMLXFRHSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- XBBAEVVIDHSGKC-UHFFFAOYSA-N [As].[Hg] Chemical compound [As].[Hg] XBBAEVVIDHSGKC-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100123568A CN1319574C (zh) | 2005-02-05 | 2005-02-05 | 一种治疗便秘的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100123568A CN1319574C (zh) | 2005-02-05 | 2005-02-05 | 一种治疗便秘的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679746A CN1679746A (zh) | 2005-10-12 |
CN1319574C true CN1319574C (zh) | 2007-06-06 |
Family
ID=35066752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100123568A Active CN1319574C (zh) | 2005-02-05 | 2005-02-05 | 一种治疗便秘的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1319574C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103478366A (zh) * | 2013-10-09 | 2014-01-01 | 北京绿源求证科技发展有限责任公司 | 一种食疗便秘的养生茶冲剂 |
CN116211949A (zh) * | 2022-05-11 | 2023-06-06 | 河北君临药业有限公司 | 一种芦荟珍珠胶囊及其制备方法 |
CN116763872A (zh) * | 2023-07-20 | 2023-09-19 | 河北君临药业有限公司 | 一种芦荟珍珠胶囊及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481870A (zh) * | 2003-07-24 | 2004-03-17 | 黄资源 | 一种治疗顽固性慢性便秘的复方中药制剂及其制备方法 |
-
2005
- 2005-02-05 CN CNB2005100123568A patent/CN1319574C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481870A (zh) * | 2003-07-24 | 2004-03-17 | 黄资源 | 一种治疗顽固性慢性便秘的复方中药制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1679746A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1051237C (zh) | 治疗癫痫病的药物 | |
CN101590168B (zh) | 一种用于治疗痛风的中药组合物及其制备方法 | |
CN101757591B (zh) | 一种治疗慢性结肠炎、直肠炎的中药组合物 | |
CN103301400A (zh) | 一种治疗慢性萎缩性胃炎的中药组合物及制备方法 | |
CN1319574C (zh) | 一种治疗便秘的药物 | |
CN101537159B (zh) | 一种中药组合物及其制备方法和应用 | |
CN101129720B (zh) | 一种治疗强直性脊柱炎的复方药物 | |
CN1814214A (zh) | 一种治疗体形消瘦、体质虚弱的中药组合物及其制备方法 | |
CN1990033A (zh) | 一种治疗高血压、血稠、动脉硬化的药物 | |
CN1255150C (zh) | 一种治疗骨质增生的中药制剂及制备方法 | |
CN104435669B (zh) | 治疗感染性休克并发多脏器功能不全综合征的中药组合物 | |
CN102670740B (zh) | 一种治疗软组织损伤的药物组合物及其制备方法 | |
CN101028349A (zh) | 治疗前列腺炎、前列腺增生的外用药物及制备方法 | |
CN1167453C (zh) | 一种治疗痔疮的散剂 | |
CN105311392A (zh) | 一种治疗三叉神经痛的中药 | |
CN1158093C (zh) | 含牦牛骨的治疗风湿病药物组合物及其制备方法 | |
CN1269518C (zh) | 一种治疗结核病的复方药物及其制备方法 | |
CN106880673A (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
CN1299755C (zh) | 一种肉桂复方药物及其制备方法和应用 | |
CN1257735A (zh) | 一种治疗便秘的药物及其制备方法 | |
CN1927366A (zh) | 一种用于慢性肠胃炎的中药组合物 | |
CN101884664A (zh) | 一种防治类风湿性关节炎的药物组合物及其制备方法 | |
CN100540038C (zh) | 治疗痔疮的药物 | |
CN100496567C (zh) | 一种治疗跌打损伤的中药片剂、胶囊及其制备方法 | |
CN1682877A (zh) | 一种治疗囊肿的药品组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Feng Shengjun Inventor after: Chen Jinchang Inventor after: Pang Qiuhua Inventor after: Pang Yirong Inventor before: Feng Shengjun Inventor before: Chen Jinchang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FENG SHENGJUN CHEN JINCHANG TO: FENG SHENGJUN CHEN JINCHANG PANG QIUHUA PANG YIRONG |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for treating constipation and preparation thereof Effective date of registration: 20170523 Granted publication date: 20070606 Pledgee: Huaxia Bank, Limited by Share Ltd, Shijiazhuang Zhengding subbranch Pledgor: Hebei Junlin Drugs Manufacturing Co., Ltd. Registration number: 2017130000007 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180514 Granted publication date: 20070606 Pledgee: Huaxia Bank, Limited by Share Ltd, Shijiazhuang Zhengding subbranch Pledgor: Hebei Junlin Drugs Manufacturing Co., Ltd. Registration number: 2017130000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for treating constipation and preparation thereof Effective date of registration: 20180524 Granted publication date: 20070606 Pledgee: Huaxia Bank, Limited by Share Ltd, Shijiazhuang Zhengding subbranch Pledgor: Hebei Junlin Drugs Manufacturing Co., Ltd. Registration number: 2018130000007 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190528 Granted publication date: 20070606 Pledgee: Huaxia Bank, Limited by Share Ltd, Shijiazhuang Zhengding subbranch Pledgor: Hebei Junlin Drugs Manufacturing Co., Ltd. Registration number: 2018130000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for treating constipation and preparation thereof Effective date of registration: 20190830 Granted publication date: 20070606 Pledgee: Xingtai Lincheng Branch of China Construction Bank Co., Ltd. Pledgor: Hebei Junlin Drugs Manufacturing Co., Ltd. Registration number: Y2019130000003 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.47 Zhongxing Street, Lincheng Economic Development Zone, Xingtai City, Hebei Province 054300 Patentee after: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. Address before: The 054300 Xingtai city of Hebei province Lincheng County Road Hebei Dragon Pharmaceutical Co. Ltd. Patentee before: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. |